In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bristol signs new deal with Five Prime involving CSFR1 antibody

Executive Summary

Replacing a deal signed in March 2014, Bristol-Myers Squibb Co. received exclusive global rights to develop and sell Five Prime Therapeutics Inc.'s Phase I colony stimulating Factor 1 receptor (CSF1R) inhibitor antibody FPA008 (cabiralizumab) for immuno-oncology indications. The agreement also includes all modifications, derivatives, fragments or variants of anti-CSFR1 antibodies.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Trial Collaborations

Related Companies